Shiniu Wei : Thank you, Sherry. Hello, everyone. For those of you following us online, we are on Slide 18. I'm going to walk you through our financial performance. In 2023, the group business continued to grow at a fast pace. The group's revenue increased by 34.2% year-over-year to about $839.5 million. Adjusted net loss of the group narrowed to about $298.2 million. Among others, the Life Science Group achieved external revenue of $404.5 million, maintaining a healthy growth rate of 15.6%. Due to the headwind in biotech funding environment, external revenue of ProBio declined to $106.7 million. External revenue of Bestzyme grew about 12.2% to $42.9 million. CARVYKTI demonstrated strong commercial potential in 2023, resulting in 144.2% explosive revenue growth for Legend. In terms of our operating profitability, the Life Science Group achieved adjusted operating profit of about $78.3 million, increasing 19.4% year-over-year. ProBio had an adjusted operating loss of about $29.7 million.